Edwards Lifesciences Corp
The FTC proposed a settlement with Edwards Lifesciences and Genesis MedTech over alleged Hart-Scott-Rodino filing violations tied to Edwards’ July 2024 $115 million acquisition of JC Medical. The FTC says a $25 million Genesis non-voting share investment was additional deal consideration, making the combined value reportable. Edwards would pay $10 million and Genesis $2 million.
Edwards Lifesciences (NYSE: EW) reported Q2 revenue of $1.74B, up 14% year over year, and adjusted EPS of 78 cents, above expectations. Full-year sales guidance was raised to 10%-11%. TAVR sales grew 11% to $1.26B. CMS draft Medicare coverage could expand TAVR access, with a final decision expected in September.
Markowitz Wayne (CVP, JAPAC) sold 9,628 shares of Edwards Lifesciences Corp (EW) at $85.06 ($0.82M total) on 2026-07-28.
Over the past 7 days, alphai's AI scored 2 news stories mentioning EW (Edwards Lifesciences Corp). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent EW coverage spans earnings, regulation and insider activity.
In the last 30 days, EW insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($1.1M). The most active reporter was Markowitz Wayne, CVP, JAPAC, with 2 filings. 25% of activity was filed under pre-arranged Rule 10b5-1 plans.
Regulatory enforcement risk rises for Edwards, with potential deal-structure scrutiny and added FTC monitoring/compliance requirements.
Guidance raise plus TAVR growth and CMS coverage draft expectations create a near-term earnings and reimbursement narrative for EW.
A routine insider open-market sale provides limited signal on fundamentals, but can slightly affect near-term sentiment.
This is a routine insider sale with no stated 10b5-1 plan, but it is not a fundamental company disclosure.
The article’s new, decision-relevant inputs are the Q2 print and the raised full-year sales growth guidance, with TMTT growth as the key driver.
alphai scores every news story that mentions EW with an AI model for sentiment and relevance, and aggregates insider trades from Edwards Lifesciences Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
The FTC proposed a settlement with Edwards Lifesciences and Genesis MedTech over alleged Hart-Scott-Rodino filing violations tied to Edwards’ July 2024 $115 million acquisition of JC Medical. The FTC says a $25 million Genesis non-voting share investment was additional deal consideration, making the combined value reportable. Edwards would pay $10 million and Genesis $2 million.
6 min readEdwards Lifesciences (NYSE: EW) reported Q2 revenue of $1.74B, up 14% year over year, and adjusted EPS of 78 cents, above expectations. Full-year sales guidance was raised to 10%-11%. TAVR sales grew 11% to $1.26B. CMS draft Medicare coverage could expand TAVR access, with a final decision expected in September.
5 min readMarkowitz Wayne (CVP, JAPAC) sold 9,628 shares of Edwards Lifesciences Corp (EW) at $85.06 ($0.82M total) on 2026-07-28.
1 min readZovighian Bernard J (CEO) sold 2,921 indirectly-held shares of Edwards Lifesciences Corp (EW) at $83.93 ($0.25M total) on 2026-07-27.
1 min readEdwards Lifesciences (NYSE:EW) reported Q2 2026 net sales of $1.74B, up 13.6% YoY, and adjusted EPS of $0.78 vs $0.74 expected. TMTT revenue rose 47.3% YoY to $195.9M. The company raised full-year sales growth guidance to 10%–11% ($6.6B–$6.9B) and reaffirmed adjusted EPS of $2.95–$3.05.
6 min readEdwards Lifesciences said the FDA cleared its Ecliptis left atrial appendage exclusion system for use during cardiac surgery to help prevent clot formation in atrial fibrillation. The company plans a preliminary launch later this year and expects to leverage its surgical valve footprint. The article also notes FDA Breakthrough designation for Aidoc’s AI and OTC Dexcom Stelo clearance for children.
3 min readEdwards Lifesciences (EW) reported Q2 2026 sales up 12.5%, driven by structural heart growth across TAVR and TMTT. Management raised full-year 2026 sales guidance to 10% to 11% and expects TMTT revenue to reach $2B by 2030. Key catalysts include U.S. TAVR NCD in September and PROGRESS trial results later in 2026.
7 min readEdwards Lifesciences reported Q2 2026 sales of $1.74 billion and 12.5% underlying growth, with adjusted EPS of $0.78. After results beat expectations, it raised full-year 2026 sales growth to 10% to 11% and net sales guidance to $6.6 billion to $6.9 billion. TAVR Q2 sales were $1.3 billion, up 10.5% YoY.
3 min readEdwards Lifesciences (NYSE:EW) reported Q2 adjusted earnings of 78 cents per share, above the 74-cent consensus, and revenue of $1.741 billion, above $1.70 billion. TAVR sales rose to $1.3 billion, and TMTT revenue increased to $195.9 million. The company reaffirmed 2026 EPS guidance at $2.95 to $3.05 and raised revenue outlook to $6.60 to $6.90.
5 min readEdwards Lifesciences (EW) shares rose about 2.2% after the company reported better-than-expected Q2 2026 results, with adjusted EPS of $0.78 versus about $0.74 consensus and revenue of $1.74B, up 12.5% YoY and above an estimated ~$1.70B. Management raised full-year sales growth guidance to 10%–11% and projected total sales of $6.6B–$6.9B. Analysts including Leerink and Piper Sandler lifted price targets to around $99–$101.
4 min read
